TP53 and B-cell chronic lymphocytic leukemia: Che et al. studied the proteomic effects of the Hsp90 inhibitor, SNX-7081, on the p53-mutated B cell CLL cell line, MEC1 (nuclear, cytosolic and mitochondrial fractions) [95].